The Quantellect read.As of Nov 19, 2026, 6 active firms cover CervoMed Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $11.00 to $31.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $21.20 sits 1362% above the current $1.45. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.27 next quarter toward $-1.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.20
+1362.1% upside
Average target across 5 active firms as of Nov 19, 2026 vs $1.45 current
Highest Target$31.00
Average Target$21.20
Lowest Target$11.00
Detailed analyst forecasts for CRVO
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate CRVO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRVO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.27
Range $-0.45 – $-0.13 · 3 analysts · -69% YoY
Next period, 3 analysts expect CervoMed Inc. to earn $-0.27 a share (range $-0.45 – $-0.13), versus $-0.86 a year earlier. Full-year consensus is $-1.76, growing to $-1.19 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering CervoMed Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRVO.
#1
Daniil Gataulin
Chardan Capital · Rank #51
Buy
$21.00+1348.3% to target
Overall win rate
52%
+ Follow
#2
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton CRVO
Overall win rate
35%
+ Follow
#3
Sumant Kulkarni
Canaccord Genuity · Rank #419
Buy
$18.00+1141.4% to target
Overall win rate
39%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$25.00+1624.1% to target
Overall win rate
36%
+ Follow
#5
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$31.00+2037.9% to target
Overall win rate
22%
+ Follow
CRVO stock forecast FAQ
What is CRVO's average 12-month price target?+
The 5 active firms with a live target average $21.20 for CervoMed Inc. over the next 12 months, ranging from a $31.00 high to a $11.00 low, as of Nov 19, 2026.
Is CRVO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRVO?+
The Street-high target is $31.00 (D. Boral Capital), and the Street-low is $11.00 (Roth Capital). The average of all 5 active-firm targets is $21.20.
How many active Wall Street firms cover CRVO?+
6 active firms have a recognized rating on CervoMed Inc. as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRVO?+
Among analysts who currently cover CRVO, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $21.00 target.
What is CervoMed Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.27 per share (range $-0.45 – $-0.13) across 3 analysts. Full-year EPS is projected at $-1.76, rising to $-1.19 the following year.
How much revenue is CervoMed Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CRVO lately?+
As of Nov 19, 2026, 6 of 6 active firms rate CRVO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRVO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.